These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24431282)

  • 41. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength.
    Kamiya N; Shuxian L; Yamaguchi R; Phipps M; Aruwajoye O; Adapala NS; Yuan H; Kim HK; Feng JQ
    Bone; 2016 Oct; 91():53-63. PubMed ID: 27402532
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
    Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
    Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Amyloid β peptide promotes bone formation by regulating Wnt/β-catenin signaling and the OPG/RANKL/RANK system.
    Yang B; Li S; Chen Z; Feng F; He L; Liu B; He T; Wang X; Chen R; Chen Z; Xie P; Rong L
    FASEB J; 2020 Mar; 34(3):3583-3593. PubMed ID: 31944393
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis.
    Day TF; Guo X; Garrett-Beal L; Yang Y
    Dev Cell; 2005 May; 8(5):739-50. PubMed ID: 15866164
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bone morphogenetic protein-2 enhances Wnt/beta-catenin signaling-induced osteoprotegerin expression.
    Sato MM; Nakashima A; Nashimoto M; Yawaka Y; Tamura M
    Genes Cells; 2009 Feb; 14(2):141-53. PubMed ID: 19170762
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
    Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
    Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Constitutive Activation of β-Catenin in Differentiated Osteoclasts Induces Bone Loss in Mice.
    Sui X; Deng S; Liu M; Fan L; Wang Y; Xu H; Sun Y; Kishen A; Zhang Q
    Cell Physiol Biochem; 2018; 48(5):2091-2102. PubMed ID: 30107384
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CCN2 enhances RANKL-induced osteoclast differentiation via direct binding to RANK and OPG.
    Aoyama E; Kubota S; Khattab HM; Nishida T; Takigawa M
    Bone; 2015 Apr; 73():242-8. PubMed ID: 25554597
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss.
    Kleyer A; Scholtysek C; Bottesch E; Hillienhof U; Beyer C; Distler JH; Tuckermann JP; Schett G; Krönke G
    J Bone Miner Res; 2012 Dec; 27(12):2442-51. PubMed ID: 22806960
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Osteoblast extracellular Ca2+ -sensing receptor regulates bone development, mineralization, and turnover.
    Dvorak-Ewell MM; Chen TH; Liang N; Garvey C; Liu B; Tu C; Chang W; Bikle DD; Shoback DM
    J Bone Miner Res; 2011 Dec; 26(12):2935-47. PubMed ID: 21956637
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin.
    Albers J; Keller J; Baranowsky A; Beil FT; Catala-Lehnen P; Schulze J; Amling M; Schinke T
    J Cell Biol; 2013 Feb; 200(4):537-49. PubMed ID: 23401003
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selenoprotein W ensures physiological bone remodeling by preventing hyperactivity of osteoclasts.
    Kim H; Lee K; Kim JM; Kim MY; Kim JR; Lee HW; Chung YW; Shin HI; Kim T; Park ES; Rho J; Lee SH; Kim N; Lee SY; Choi Y; Jeong D
    Nat Commun; 2021 Apr; 12(1):2258. PubMed ID: 33859201
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Beta-catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing.
    Chen Y; Whetstone HC; Lin AC; Nadesan P; Wei Q; Poon R; Alman BA
    PLoS Med; 2007 Jul; 4(7):e249. PubMed ID: 17676991
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels.
    Kondo T; Kitazawa R; Yamaguchi A; Kitazawa S
    J Cell Biochem; 2008 Jan; 103(1):335-45. PubMed ID: 17516544
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Conditional deletion of E11/Podoplanin in bone protects against ovariectomy-induced increases in osteoclast formation and activity.
    Staines KA; Hopkinson M; Dillon S; Stephen LA; Fleming R; Sophocleous A; Buttle DJ; Pitsillides AA; Farquharson C
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894854
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oscillatory fluid flow-induced shear stress decreases osteoclastogenesis through RANKL and OPG signaling.
    Kim CH; You L; Yellowley CE; Jacobs CR
    Bone; 2006 Nov; 39(5):1043-1047. PubMed ID: 16860618
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Elevated Gα11 expression in osteoblast lineage cells promotes osteoclastogenesis and leads to enhanced trabecular bone accrual in response to pamidronate.
    Dela Cruz A; Grynpas MD; Mitchell J
    Am J Physiol Endocrinol Metab; 2016 May; 310(10):E811-20. PubMed ID: 27006198
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Only the Co-Transcriptional Activity of β-Catenin Is Required for the Local Regulatory Effects in Hypertrophic Chondrocytes on Developmental Bone Modeling.
    Wolff LI; Houben A; Fabritius C; Angus-Hill M; Basler K; Hartmann C
    J Bone Miner Res; 2021 Oct; 36(10):2039-2052. PubMed ID: 34155688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.